Inside the research
Alkermes plc
ALKS Research profile · latest available data
Price overview
$40.85
▲ +0.06 (+0.1%)
| 52w hi | $55.22 |
|---|---|
| 52w lo | $27.13 |
| Vol | 2.59M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.00
| Short | +0.13 |
|---|---|
| Medium | +0.04 |
| Long | -0.32 |
computed 2026-09-27
Key fundamentals
Alkermes plc
Healthcare · Drug Manufacturers - Specialty & Generic
| Market cap | $6.85B |
|---|---|
| Enterprise value | $7.77B |
| Trailing P/E | 107.50x |
| Forward P/E | 22.59x |
| EV / EBITDA | 27.27x |
| P / S (ttm) | 4.11x |
| Profit margin | 4.0% |
| Return on equity | 3.9% |
| Revenue growth | +27.0% |
| Earnings growth | -99.4% |
| Debt / equity | 86.95 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.01 | |
| Sector | +0.08 | |
| Technical | -0.05 | |
| Earnings | +0.00 | |
| Sentiment | +0.19 |
macro × 1.00 · 2026-09-27
Business overview
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Risk Metrics
| Beta vs SPX | 0.72 |
|---|---|
| Corr SPX | 0.30 |
| Annual vol | 38.1% |
| Annual ret | +25.1% |
| Sharpe | 0.66 |
| Max DD | -27.4% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $45.35 |
|---|---|
| High / Low | $58.00 / $34.00 |
| Median | $45.00 |
| Analysts | 17 |
| Strong Buy | 2 | |
|---|---|---|
| Buy | 12 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-06 | Wells Fargo | → Overweight |
| 2026-05-06 | UBS | → Buy |
| 2026-05-06 | Needham | → Buy |
| 2026-04-09 | B of A Securities | → Neutral |
| 2026-03-24 | Piper Sandler | → Overweight |
| 2026-02-26 | Wells Fargo | → Overweight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-12 | Material Agreement, Exhibits | read |
| 2026-07-28 | Earnings Release, Exhibits | read |
| 2026-07-08 | Termination of Agreement | read |
| 2026-06-15 | Reg FD Disclosure, Other Material Event… | read |
| 2026-05-20 | Officer / Director Change, Shareholder Vote… | read |
| 2026-05-12 | Reg FD Disclosure, Other Material Event… | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-02-25 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-02-25 | Earnings Release, Exhibits | read |
| 2026-02-12 | Material Agreement, Termination of Agreement… | read |
| 2026-01-12 | Earnings Release, Reg FD Disclosure… | read |
| 2026-01-06 | Reg FD Disclosure, Other Material Event… | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-03 | snyderman nancy lynn MD | Option exercise | 27.95K | $1.31M | |
| 2026-08-03 | snyderman nancy lynn MD | Option exercise | 16.52K | $772.00K | |
| 2026-08-03 | snyderman nancy lynn MD | Sell | 44.47K | $2.24M | |
| 2026-08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Of | Option exercise | 104 | $2.01K |
| 2026-08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Of | Option exercise | 4.90K | $120.39K |
| 2026-08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Of | Sell | 9.00K | $437.22K |
| 2026-08-03 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2.03K | $98.81K |
| 2026-07-06 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2.03K | $109.90K |
| 2026-07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Of | Option exercise | 5.00K | $96.70K |
| 2026-07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Of | Sell | 8.30K | $427.13K |
Flow & Concentration
| Insider 180d net | -$4.59M |
|---|---|
| Insider buys / sells | 0 / 10 |
| Insider bias | Sellers |
| 13F holders | 8 |
| Top-5 share | 97.3% |
| HHI | 3,434 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $479.97M | 9.16M |
| Renaissance Technologies | $338.52M | 6.46M |
| Citadel Advisors | $99.13M | 1.89M |
| Fidelity / FMR LLC | $59.44M | 1.13M |
| Millennium Management | $18.06M | 344.60K |
| Capital Research / Capital World | $15.74M | 300.35K |
| AQR Capital Management | $11.16M | 212.97K |
| T. Rowe Price Group | $353.00K | 6.74M |
As of 2026-06-30
SEC Filings
The Long Run
FY 2011–2025 · 14 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $1.48B | +10.8% | |
| Operating income | $253.96M | -38.7% | |
| Net income | $241.66M | +139.2% | |
| Cash from ops | $439.12M | +56.4% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $40.94 | $41.12 | $40.49 | $40.85 | 2.59M |
| Sep 24 | $42.55 | $42.55 | $40.59 | $40.79 | 2.84M |
| Sep 23 | $43.20 | $43.62 | $41.23 | $42.13 | 2.48M |
| Sep 22 | $44.39 | $44.53 | $43.08 | $43.29 | 2.31M |
| Sep 21 | $44.27 | $44.79 | $43.11 | $44.18 | 3.73M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →